ArticleCellular and molecular neurobiology2026
Fecal miRNome and Proteome Profiling Uncovers Stage-Specific Biomarkers of Alzheimer's Disease in 3×Tg-AD Mice.
Article in Cellular and molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reliable, minimally invasive biomarkers for Alzheimer's disease (AD) remain a critical unmet need. Considering mounting evidence for gut-brain interactions in AD, we explored whether fecal samples contain host-derived molecular signals that reflect disease-related changes and could serve as accessible biomarkers. Fecal small RNA sequencing and quantitative proteomics were performed in symptomatic 15-month-old 3×Tg-AD mice and controls. Pathway and network analyses identified key dysregulated molecules. Selected miRNAs and proteins were validated by qPCR or Western blotting in independent pre-symptomatic, early symptomatic, and severe cohorts. To assess whether fecal signals mirrored tissue alterations, colon samples were analyzed for tight-junction proteins, inflammatory markers, epigenetic regulation, and expression of selected miRNAs and proteins. Multi-omics identified 31 miRNAs and 81 proteins modulated in AD fecal sample, revealing a distinct AD-associated fecal signature involving pathways linked to neuroinflammation, synaptic dysfunction, vascular imbalance, and metabolism. Several miRNAs- including miR-322-5p, miR-194-1 and miR-223-3p were significantly altered and validated across disease stages (3-,7-,15-old months mice, respectively). Notably, miR-146b-5p expression is inversely correlated with AD severity, exhibiting a stepwise decline from asymptomatic individuals to those with mild and severe stages. IgKappa and Ela3B emerged as the strongest protein candidates, showing opposite and progressive modulation. Notably, IgKappa and miR-146b showed the most consistent trajectories. Colon analyses uncovered reduced Claudin-7, strong IgKappa upregulation driven by enhancer hypomethylation, and partial overlap between fecal and tissue miRNA profiles, indicating that fecal signals reflect subtle epithelial and immune perturbations associated with AD. Multi-omics at severe stage and a stage specific validation support fecal miRNAs and proteins as promising, host-derived biomarkers for AD. Fecal profiling offers a practical, repeatable, and low-cost approach with translational potential for early detection and longitudinal monitoring in neurodegeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.